A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), AnEGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with UnresectableLocally Advanced or Metastatic Cancer

Project: Research project

Project Details

Description

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
StatusActive
Effective start/end date9/28/235/31/33

Funding

  • TAKEDA DEVELOPMENT CENTER AMERICAS, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.